OncoMatch/Clinical Trials/NCT06368817
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma
Is NCT06368817 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Carboplatin and Etoposide for basal ganglia germinoma.
Treatment: Carboplatin · Etoposide — This phase II trial studies how well lower dose radiotherapy after chemotherapy (Carboplatin \& Etoposide) works in treating children with central nervous system (CNS) germinomas. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Researchers want to see if lowering the dose of standard radiotherapy (RT) after chemotherapy can help get rid of CNS germinomas with fewer long-term side effects.
Check if I qualifyExtracted eligibility criteria
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: tumor-directed therapy
Exception: surgical intervention and corticosteroids allowed
Patients who have received any prior tumor-directed therapy for their diagnosis of germinoma other than surgical intervention and corticosteroids are not eligible
Lab requirements
Blood counts
ANC ≥ 1000/uL; Platelet count ≥ 100,000/uL (transfusion independent); Hemoglobin ≥ 8.0 g/dL (may receive RBC transfusions)
Kidney function
Pediatric (3-17y): serum creatinine by age/sex OR 24h urine creatinine clearance ≥ 70 mL/min/1.73 m^2 OR GFR ≥ 50 mL/min/1.73 m^2 (direct measurement); Adult (≥18y): creatinine clearance ≥ 70 mL/min (Cockcroft-Gault or 24h urine)
Liver function
Total bilirubin ≤ 1.5 x ULN for age; SGPT (ALT) ≤ 135 U/L (ULN for SGPT (ALT) set to 45 U/L)
For patients with solid tumors: Peripheral absolute neutrophil count (ANC) ≥ 1000/uL... Platelet count ≥ 100,000/uL (transfusion independent)... Hemoglobin ≥ 8.0 g/dL... serum creatinine based on age/sex... creatinine clearance ≥ 70 mL/min... Total bilirubin ≤ 1.5 x ULN for age... SGPT (ALT) ≤ 135 U/L (ULN for SGPT (ALT) set to 45 U/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- USA Health Strada Patient Care Center · Mobile, Alabama
- Phoenix Childrens Hospital · Phoenix, Arizona
- Arkansas Children's Hospital · Little Rock, Arkansas
- Loma Linda University Medical Center · Loma Linda, California
- Children's Hospital Los Angeles · Los Angeles, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify